Chongqing Lummy Pharmaceutical(300006) Key Financial Indicators

Quotes

Detailed Quotes

Company Overview

Company Profile Company Executives

Financial Analysis

Main Composition Key Indicators Financial Statement

Multi-dimentional Analyses

Company Valuation Capital Tracking Short Selling Data

YOY

Do not show

Hide blank lines

(Q3)2023/03/31(FY)2022/12/31(Q9)2022/09/30(Q6)2022/06/30

Per Share Indicator

Net Asset Per Share

-0.33% 2.0105 -1.48% 2.012 -5.48% 2.0267 -7.43% 1.9957

Basic Earning Per Share

86.40% -0.0034 35.54% -0.0651 -272.68% -0.0354 -234.01% -0.0465

Diluted Earning Per Share

86.40% -0.0034 35.54% -0.0651 -272.68% -0.0354 -234.01% -0.0465

Earning Per Share

86.40% -0.0034 31.62% -0.0651 -287.30% -0.0354 -251.47% -0.0465

Diluted Earning Per Share（TTM）

73.87% -0.0435 31.62% -0.0651 48.64% -0.1495 36.41% -0.1724

Capital Surplus Funds Per Share

1.23% 1.3987 1.09% 1.3967 -0.04% 1.3817 -0.04% 1.3817

Undivided Profit Per Share

-5.68% -0.4393 -11.57% -0.4359 -40.46% -0.4062 -57.61% -0.4372

Operating Cash Flow Per Share

175.83% 0.0091 -47.22% 0.0541 -140.03% -0.0251 -800.00% -0.0609

Enterprise FCF Per Share

-39.15% -0.0263 211.94% 0.2034 85.89% -0.0238 103.97% 0.0067

Shareholder FCF Per Share

-117.84% -0.0203 134.05% 0.3443 114.52% 0.135 117.85% 0.1603

EBIT Per Share

77.57% -0.0059 22.46% -0.0642 -201.86% -0.0438 -202.76% -0.0559

Profitability

ROE Weighted

86.18% -0.170% 38.55% -3.220% -271.57% -1.750% -226.37% -2.300%

ROE

86.19% -0.171% 30.63% -3.234% -298.00% -1.746% -263.65% -2.329%

ROA

74.63% -0.248% 26.87% -2.551% -370.91% -1.500% -283.12% -1.847%

ROIC

78.17% -0.247% 24.78% -2.745% -251.56% -1.859% -229.79% -2.392%

Net Profit Ratio

77.00% -3.356% 0.26% -8.624% -450.56% -6.667% -362.08% -13.481%

Gross Income Ratio

-3.48% 70.781% 2.84% 73.498% 3.94% 73.336% 0.04% 71.626%

EBIT To Total Operating Revenue

80.20% -2.772% -7.48% -7.668% -235.51% -6.900% -254.71% -14.523%

Period Costs Rate

-12.10% 73.733% 5.90% 84.472% 7.33% 80.943% 10.75% 82.336%

Operating Expense Rate

-2.44% 55.552% 2.76% 59.917% 2.92% 58.600% 2.64% 58.052%

Admini Expense Rate

-15.21% 12.579% 27.48% 14.894% 36.97% 14.262% 40.14% 14.460%

Financial Expense Rate

-146,255.56% -1.315% -65.87% 0.543% -101.45% -0.032% -97.14% 0.089%

Recurrent Net Profit

70.75% -8.86M 16.43% -115.33M -41.01% -70.08M -94.56% -57.1M

Operating Profit Ratio

89.79% -1.427% -89.65% -10.857% -446.29% -9.987% -332.76% -14.924%

EBIT

77.41% -6.28M 22.40% -67.83M -201.95% -46.29M -202.75% -59.03M

Solvency

Current Ratio

-12.99% 2.4457 -3.88% 2.4895 -6.72% 2.7174 2.43% 2.8518

Quick Ratio

-13.76% 2.1893 -6.48% 2.2008 -3.44% 2.4577 3.72% 2.5399

Debt Equity Ratio

9.28% 41.354% 23.25% 39.819% 33.76% 37.800% 19.06% 39.213%

Interest Cover（T）

-- -- -94.08% -9.1432 -- -- -1,234.68% -35.2305

Shareholders Equity Without Minority Interests To Total Liabilities

-8.76% 235.311% -19.07% 244.183% -25.55% 256.796% -16.20% 248.925%

Shareholders Equity Without Minority Interests To Interest Bear Debt

-7.02% 581.5221% -49.07% 592.2632% -43.57% 565.9528% -21.87% 557.1879%

Long Debt To Working Capital

-17.67% 0.1383 258.34% 0.1617 219.09% 0.1522 253.90% 0.198

Growth Ability

Average Net Profit YOY Past Five Year

-26.57% 92.663% 40.14% 94.519% 1,637.66% 707.178% 187.57% 94.343%

Operating Capacity

Operating Cycle（D/T）

-12.07% 405.7426 17.08% 429.8257 1.08% 408.4451 9.57% 446.7755

Inventory Turnover Days（D/T）

-4.23% 268.516 18.19% 276.5412 -6.67% 248.5844 -0.25% 273.9013

Accounts Receivable Turnover Days（D/T）

-24.22% 137.2266 15.12% 153.2845 16.06% 159.8607 29.83% 172.8742

Inventory turnover Rate（T）

4.42% 0.3352 -15.39% 1.3018 7.15% 1.0862 0.26% 0.6572

Accounts Receivable Turnover Rate（T）

31.95% 0.6558 -13.13% 2.3486 -13.83% 1.689 -22.98% 1.0412

Current Assets Turnover Rate（T）

11.65% 0.1265 -28.81% 0.5095 -26.34% 0.3809 -30.87% 0.2327

Total Assets Turnover Rate（T）

10.15% 0.0738 -26.56% 0.2958 -22.64% 0.2249 -30.03% 0.137

Fixed Assets Turnover Rate（T）

-- -- -15.48% 2.5347 -- -- -24.58% 1.1211

Equity Turnover Rate（T）

15.10% 0.1067 -43.88% 0.4133 -39.84% 0.3123 -46.28% 0.1907

Cash Position

Free Cash Flow

-39.34% -27.76M 211.92% 214.78M 85.88% -25.17M 103.99% 7.11M

Operating Revenue Cash Cover

-25.31% 97.503% 5.98% 121.105% 3.59% 114.474% 10.33% 121.654%

Operating Cash In To Assets

173.02% 0.312% -46.34% 1.910% -141.23% -0.890% -837.21% -2.168%

Dividend Ability

Capital Structure

Debt Assets Ratio

6.57% 29.256% 16.63% 28.479% 24.50% 27.431% 13.69% 28.168%

Current Assets To Total Assets

0.78% 59.627% -3.17% 57.136% 0.47% 59.098% -6.28% 58.774%

Non Current Assets To Total Assets

-1.13% 40.374% 4.56% 42.865% -0.67% 40.903% 10.57% 41.226%

Fix Assets Ratio

-- -- -17.02% 10.605% -- -- -4.99% 11.681%

Interest Bearing Debt To Total Capital

6.20% 14.335% 82.35% 14.102% 65.28% 14.640% 23.57% 14.907%

Yield Quality

Dupont Analysis

Equity Multipler_DuPont

4.38% 1.445% -23.57% 1.397% -22.27% 1.388% -23.25% 1.391%

Net Profit of Parent Company OwnersTo Net Profit_DuPont

-47.54% 47.779% -5.09% 90.068% -29.04% 83.555% -12.96% 89.558%

Net Profit To Total Operating Revenue_DuPont

77.00% -3.356% 0.26% -8.624% -450.57% -6.667% -362.08% -13.481%

EBIT To Total Operating Revenue_DuPont

80.20% -2.772% -7.48% -7.668% -235.51% -6.900% -254.71% -14.523%

Currency Unit

CNYCNYCNYCNY

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%

Company Overview More

Production and sales (limited to the company's own production) powder injections, tablets, high-volume injections, small-volume injections (including antitumor drugs), freeze-dried powder injections (including anti-tumor drugs, containing hormones), capsules***

CEO： --

Market： --

Listing Date： 10/30/2009

Futu Hot List

CNHKUS

SearchNews

SymbolLatest price%Chg

Watchlist